Proteome Sciences PLC Director/PDMR Shareholding (8464U)

TIDMPRM

RNS Number : 8464U

Proteome Sciences PLC

27 October 2017

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 24 October 2017 and 25 October 2017, it purchased 75,000 and 109,460 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.18p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 55,197,431 equivalent to 18.69% of Proteome Sciences' total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 55,197,431 Ordinary Shares of the Company representing 18.69% of the issued share capital of the Company.

 
1.  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name                                                      Vulpes Life Sciences Fund 
2.  Reason for the Notification 
a)  Position/status                                           PCA of Martin Diggle (NED) 
b)  Initial notification/Amendment                            Initial notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                                      Proteome Sciences plc 
b)  LEI                                                       213800Q62ICXANKU2986 
4.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
     each type of transaction; (iii) each date; and (iv) each place where transactions have been 
     conducted 
a)  Description of the Financial instrument, type of          Ordinary Shares of 1p each 
    instrument 
    Identification code                                       GB0003104196 
b)  Nature of the transaction                                 Purchase of shares 
c)  Price(s) and volume(s)                                    75,000 Ordinary Shares at 3.11p per Ordinary Share 
                                                               109,460 Ordinary Shares at 3.25p per Ordinary Share 
d)  Aggregated information: 
     -- Aggregated volume                                      184,460 Ordinary Shares of 1p each purchased at an 
     -- Price                                                  average price of 3.18p per Ordinary Share 
e)  Date of the transaction                                   24, 25 October 2017 
f)  Place of the transaction                                  London Stock Exchange, AIM Market (XLON) 
 
 
For further information: 
 Proteome Sciences plc 
Jeremy Haigh, Chief Executive Officer 
 Tel: [phone] 
Ian Pike, Chief Scientific Officer 
Stefan Fuhrman, Interim Finance Director 
 
  finnCap Limited (Nominated Adviser/Broker) 
Geoff Nash/James Thompson                         Tel: +44 (0)20 
                                                     7220 0500 
Tony Quirke (broking) 
 IFC Advisory (Financial PR and IR) 
Tim Metcalfe/Graham Herring/Miles Nolan                Tel: +44 (0)20 
                                                        3053 8671 
 
 

Notes for editors:

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) ) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator(TM) ). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHFESFSWFWSEES

(END) Dow Jones Newswires

October 27, 2017 06:30 ET (10:30 GMT)